Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

Leukemia

Volumn 27, Issue 6, 2013, Pages 1254-1262

  Pfeifer, H ^a   Wassmann, B ^a   Bethge, W ^b   Dengler, J ^c   Bornhauser M ^d   Stadler, M ^e   Beelen, D ^f   Vucinic, V ^g   Burmeister, T ^h   Stelljes, M ⁱ   Faul, C ^b   Dreger, P ^c   Kiani, A ^d   Schafer Eckart K ^j   Schwerdtfeger, R ^k   Lange, E ^l   Kubuschok, B ^m   Horst, H A ⁿ   Gramatzki, M ⁿ   Bruck P ^a   Serve, H ^a   Hoelzer, D ^a   Gokbuget N ^a   Ottmann, O G ^a   more..

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^h Department of Hematology   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j KLINIKUM NÜRNBERG   (Germany)

^k DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^l Evangelisches Krankenhaus Hamm   (Germany)

^m SAARLAND UNIVERSITY   (Germany)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

BCR ABL1; minimal residual disease; Philadelphia chromosome; tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IMATINIB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CANCER PREVENTION; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; INTERVENTION STUDY; KIDNEY DYSFUNCTION; LEUKEMIA RELAPSE; LIVER DYSFUNCTION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MORBIDITY; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PAPILLEDEMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA HEMORRHAGE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BENZAMIDES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PATIENT COMPLIANCE; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84878915659     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.352     Document Type: Article

References (34)

1. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408-1413. (Pubitemid 46239571)
2. Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19: 1509-1516. (Pubitemid 43090392)
3. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449-3457. (Pubitemid 40628185)
4. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 2006; 20: 400-403. (Pubitemid 43291735)
5. Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph ALL). Blood 2006; 108: 1469-1477. (Pubitemid 44316110)
6. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460-466. (Pubitemid 46630465)
7. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R et al. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph) acute lymphoblastic leukemia. Blood 2010; 116: 2070-2077.
8. Delannoy A, Delabesse E, Lheritier V, Castaigne S, Rigal-Huguet F, Raffoux E et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006; 20: 1526-1532. (Pubitemid 44264094)
9. Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 2009; 21(Suppl 1): S43-S46.
10. Ottmann OG, Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL). Hematology Am Soc Hematol Educ Program 2009; 371-381.
11. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009; 113: 4489-4496.
12. Bassan R, Rossi G, Pogliani EM, Di BE, Angelucci E, Cavattoni I et al. Chemotherapyphased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28: 3644-3652.
13. Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95: 87-95.
14. Esperou H, Boiron JM, Cayuela JM, Blanchet O, Kuentz M, Jouet JP et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003; 31: 909-918. (Pubitemid 36675748)
15. Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120: 145-153. (Pubitemid 36056923)
16. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiationetoposide regimen. Blood 2008; 112: 903-909.
17. Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosomepositive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 867-872. (Pubitemid 41655612)
18. Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring UJ et al. Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive acute lymphoblastic leukemia (Ph ALL). Blood 2005; 106: 458-463. (Pubitemid 40981238)
19. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551. (Pubitemid 43882350)
20. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110: 2309-2315. (Pubitemid 47523149)
21. Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89: 2602-2609. (Pubitemid 27143311)
22. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev 2005; 19: 289-300. (Pubitemid 41571930)
23. Peggs KS, Mackinnon S. Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol 2001; 8: 349-354. (Pubitemid 33032915)
24. Nakasone H, Kanda Y, Takasaki H, Nakaseko C, Sakura T, Fujisawa S et al. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia 2010; 24: 1236-1239.
25. Imahashi N, Tokunaga M, Nishiwaki S, Yanagisawa M, Ozawa Y, Miyamura K. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. Rinsho Ketsueki 2009; 50: 1612-1615.
26. Yoshimitsu M, Fujiwara H, Ozaki A, Hamada H, Matsushita K, Arima N et al. Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol 2008; 88: 331-335.
27. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791-2793. (Pubitemid 46482072)
28. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph ALL). Blood 2007; 110: 727-734. (Pubitemid 47108165)
29. Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (PhALL). Cancer 2007; 109: 2068-2076. (Pubitemid 46745234)
30. Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Atta J, Petershofen EK et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood 2003; 101: 85-90. (Pubitemid 36025891)
31. Nishiwaki S, Miyamura K, Kato C, Terakura S, Ohashi K, Sakamaki H et al. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Anticancer Res 2010; 30: 2415-2418.
32. Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve diseasefree survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. J Hematol Oncol 2012; 5: 29.
33. Savani BN, Srinivasan R, Espinoza-Delgado I, Dorrance C, Takahashi Y, Igarashi T et al. Treatment of relapsed blast-phase Philadelphia-chromosome- positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncol 2005; 6: 809-812. (Pubitemid 41430722)
34. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia- positive acute lymphoblastic leukemia (Ph ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2009; 33: 174-177.